6月5日,智翔金泰(股票代码:688443)宣布,与纳斯达克上市公司Cullinan Therapeutics,Inc.(纳斯达克股票代码:CGEM;以下简称“Cullinan”)达成海外授权合作协议。根据协议,Cullinan将获得智翔金泰抗BCMA×CD3双特异性抗体——GR1803注射液(Velinotamig)在大中华区(包括中国内地、香港、澳门及台湾地区)以外的全球开发、生产及商业化权益...
Source Link6月5日,智翔金泰(股票代码:688443)宣布,与纳斯达克上市公司Cullinan Therapeutics,Inc.(纳斯达克股票代码:CGEM;以下简称“Cullinan”)达成海外授权合作协议。根据协议,Cullinan将获得智翔金泰抗BCMA×CD3双特异性抗体——GR1803注射液(Velinotamig)在大中华区(包括中国内地、香港、澳门及台湾地区)以外的全球开发、生产及商业化权益...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.